ES2196014T3 - Vectores de virus espumosos recombinantes para usos medicos y de diagtico y procedimiento de preparacion de vectores de virus espumosos recombinantes. - Google Patents

Vectores de virus espumosos recombinantes para usos medicos y de diagtico y procedimiento de preparacion de vectores de virus espumosos recombinantes.

Info

Publication number
ES2196014T3
ES2196014T3 ES94107918T ES94107918T ES2196014T3 ES 2196014 T3 ES2196014 T3 ES 2196014T3 ES 94107918 T ES94107918 T ES 94107918T ES 94107918 T ES94107918 T ES 94107918T ES 2196014 T3 ES2196014 T3 ES 2196014T3
Authority
ES
Spain
Prior art keywords
sparkling
viruses
preparation
recombinant
vometers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94107918T
Other languages
English (en)
Inventor
Meulen Volker Prof Dr Ter
Axel Dr Rethwilm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2196014T3 publication Critical patent/ES2196014T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
    • C12N2740/17022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
    • C12N2740/17041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/17043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/80—Vectors comprising a special translation-regulating system from vertebrates
    • C12N2840/85—Vectors comprising a special translation-regulating system from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LA PREPARACION DE NUEVOS SISTEMAS DE VECTORES QUE SE GENERAN MEDIANTE UNA RECOMBINACION IN VITRO, UTILIZANDO TECNICAS GENETICAS, DE ACIDOS NUCLEICOS A PARTIR DE ESPECIES DE VIRUS ESPUMOSOS Y DE ACIDO NUCLEICO EXOGENO Y SE PRODUCEN MEDIANTE CELULAS HUESPEDES ADECUADAS O MEDIANTE LINEAS CELULARES DE FUSION ALTERADAS DE FORMA RECOMBINANTE. LA PREPARACION RECOMBINANTE DE LINEAS CELULARES DE FUSION PARTICULARMENTE ADECUADAS TAMBIEN FORMA PARTE DE ESTA INVENCION. LA INVENCION SE CARACTERIZA POR LA TRANSFERENCIA SEGURA Y EFICIENTE A TRAVES DE VECTORES DE VIRUS ESPUMOSOS DE GENES TERAPEUTICOS O DE CUALQUIER OTRO TIPO DE GENES EN CELULAS EUCARIOTICAS.
ES94107918T 1993-06-03 1994-05-24 Vectores de virus espumosos recombinantes para usos medicos y de diagtico y procedimiento de preparacion de vectores de virus espumosos recombinantes. Expired - Lifetime ES2196014T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4318387A DE4318387A1 (de) 1993-06-03 1993-06-03 Rekombinante Foamy Virus Vektoren für medizinische und diagnostische Anwendungen sowie Verfahren zur Herstellung von rekombinanten Foamy Virus Vektoren

Publications (1)

Publication Number Publication Date
ES2196014T3 true ES2196014T3 (es) 2003-12-16

Family

ID=6489499

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94107918T Expired - Lifetime ES2196014T3 (es) 1993-06-03 1994-05-24 Vectores de virus espumosos recombinantes para usos medicos y de diagtico y procedimiento de preparacion de vectores de virus espumosos recombinantes.

Country Status (10)

Country Link
US (1) US5646032A (es)
EP (1) EP0632129B1 (es)
JP (2) JPH06343477A (es)
AT (1) ATE237693T1 (es)
CA (1) CA2124769C (es)
DE (2) DE4318387A1 (es)
DK (1) DK0632129T3 (es)
ES (1) ES2196014T3 (es)
PT (1) PT632129E (es)
SI (1) SI0632129T1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707091B1 (fr) 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
FR2727429B1 (fr) 1994-11-30 1997-11-28 Haguenauer Odile Cohen Lignees d'encapsidation et vecteurs d'expression pour la transcomplementation de vecteurs retroviraux defectifs
DE19503082A1 (de) 1995-02-01 1996-08-08 Univ Ludwigs Albert Gegenstand und Verfahren zur bevorzugt transienten Expression und möglichen Translation spezifischer RNA im cytoplasmatischen Bereich höherer eukaryontischer Zellen
US5888767A (en) * 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
CA2190304A1 (en) * 1995-12-15 1997-06-16 Elazar Rabbani Property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses
US6492165B1 (en) 1997-02-12 2002-12-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Retrovirus isolated from humans
US5882912A (en) * 1997-02-12 1999-03-16 Center For Disease Control And Prevention Retrovirus isolated from humans
JP3954151B2 (ja) * 1997-03-14 2007-08-08 トランスジエヌ・エス・アー フォーミーウイルスエンベロープタンパク質の発現
WO2000024876A2 (en) 1998-10-27 2000-05-04 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Spumavirus isolated from humans
DE19858441C2 (de) * 1998-12-17 2001-02-15 Deutsches Krebsforsch FV-Vektoren zur Expression von Fremdgenen in Säugern und deren Verwendung
WO2000041732A1 (en) * 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
US6800475B1 (en) 1999-06-14 2004-10-05 The United States Of America As Represented By The Department Of Health And Human Services Isolation of a human retrovirus
AU2003267976A1 (en) * 2002-06-27 2004-01-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Live replicating spumavirus vector
AU2003268531A1 (en) 2002-09-06 2004-03-29 University Of South Florida Materials and methods for treatment of allergic diseases
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US20050272650A1 (en) * 2004-02-17 2005-12-08 Mohapatra Shyam S Materials and methods for treatment of inflammatory and cell proliferation disorders
EP1750748A1 (en) * 2004-06-04 2007-02-14 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of the foamy virus bet protein for inactivating apobec
CA2656990A1 (en) * 2006-04-28 2007-11-08 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
CN111093715A (zh) * 2017-09-18 2020-05-01 儿童医院医疗中心 强绝缘子和其在基因递送中的用途

Also Published As

Publication number Publication date
DK0632129T3 (da) 2003-08-04
ATE237693T1 (de) 2003-05-15
JP2007082562A (ja) 2007-04-05
EP0632129A1 (en) 1995-01-04
US5646032A (en) 1997-07-08
PT632129E (pt) 2003-08-29
EP0632129B1 (en) 2003-04-16
DE69432500T2 (de) 2003-11-20
CA2124769C (en) 2007-07-10
DE69432500D1 (de) 2003-05-22
SI0632129T1 (en) 2003-08-31
DE4318387A1 (de) 1994-12-08
CA2124769A1 (en) 1994-12-04
JPH06343477A (ja) 1994-12-20

Similar Documents

Publication Publication Date Title
ES2196014T3 (es) Vectores de virus espumosos recombinantes para usos medicos y de diagtico y procedimiento de preparacion de vectores de virus espumosos recombinantes.
BR0010725A (pt) Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
EE05138B1 (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin
DE69836588D1 (de) Tuberkulose impfstoff
DK2295065T3 (da) Modificeret varmechockprotein-antigenpeptidkompleks
NO20001768L (no) Viruskapsomervaksine, fremgangsmÕte til fremstilling samt anvendelse derav
BR9913331A (pt) Expressão e exportação de inibidores de angiogênese como imunofusinas
BR0007414A (pt) Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
WO1995007718A3 (en) Purine nucleoside phosphorylase gene therapy for human malignancy
ATE284954T1 (de) Hyaluronan synthase gen und seine verwendung
AU3431497A (en) DNA immunization against Chlaymdia infection
EP2053124A3 (en) Recombinant RSV virus expression systems and vaccines
DK0843731T3 (da) Adenovirusvektorer til genterapi
EP1015009A4 (en) attenuated VIF DNA immunization cassettes as genetic vaccines
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
HK41897A (en) Methods for isolating herpes virus thymidine kinase-encoding DNA
BR9806084A (pt) Vetor de poliovirus sabin tipo i, recombinante ou quimérico de replicação competente, seus métodos de produção e célula hospedeira
EP0336383A3 (en) Novel recombinant human lymphotoxin
Lasky et al. Production of an HSV subunit vaccine by genetically engineered mammalian cell lines.
BR9915970A (pt) Vìrus recombinante expressando dna exógenocodificando cd80 felino, ctla-4 felino ou cd86 felinoe usos do mesmo
Moss et al. Vaccinia virus vectors: Potential use as live recombinant virus vaccines.
Leung et al. A direct cloning-expression system for neutralization antigens of herpes simplex viruses.
Barsomian et al. Endo F-free PNGase
NO179453C (no) Fremgangsmåte for fremstilling av terapeutisk aktivt amphiregulin, vertscelle som produserer proteinet, rekombinant vektor inneholdt i vertscellen, samt nukleotidsekvens som koder for proteiner med amphiregulinaktivitet